At the same time, with the advent of next generation sequencing, clinical laboratories have increasingly adopted next generation sequencing as a more comprehensive acute myeloid leukemia genetic testing method, given its ability to simultaneously evaluate multiple clinically informative markers, such as NPM1, CEBPA, KIT, TP53, AXSL1, RUNX1, IDH1, and IDH2 [20]. This evidence concerns the gene NPM1 and acute myeloid leukemia.